EDO’s Preclinical Pipeline
There are three molecules in the EDO pipeline:
1. EDO-S101 is our leading project being developed for the treatment of haematological malignancies and solid tumours. It is a representative of the A-DAC principle, a new approach in chemotherapy that uses fusion technology to combine an alkylating agent with a pan-histone deacetylase inhibitor (HDAC) to simultaneously damage DNA and block damage repair. The combination of the two different modes of action has the potential to overcome resistance towards other conventional chemotherapies.
2. EDO-B776 is an antibody-drug conjugate (ADC) targeting a fragment of cancer antigen 125 (CA125) and is being developed to treat ovarian cancer.
3. EDO-B278 is an ADC targeting the human tissue factor and is in development to treat various solid tumours.